# Study of Immune Modulatory Drugs and Other Treatments in COVID-19 Patients: Sarilumab, Azithromycin, Hydroxychloroquine Trial - CORIMUNO-19 - VIRO

> **NCT04341870** · PHASE2,PHASE3 · SUSPENDED · sponsor: **Assistance Publique - Hôpitaux de Paris** · enrollment: 27 (actual)

## Conditions studied

- COVID19
- SARS-CoV-2 Infection

## Interventions

- **DRUG:** Sarilumab
- **DRUG:** Azithromycin
- **DRUG:** Hydroxychloroquine

## Key facts

- **NCT ID:** NCT04341870
- **Lead sponsor:** Assistance Publique - Hôpitaux de Paris
- **Sponsor class:** OTHER
- **Phase:** PHASE2,PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** SUSPENDED
- **Start date:** 2020-04-11
- **Primary completion:** 2020-05-08
- **Final completion:** 2020-08
- **Target enrollment:** 27 (ACTUAL)
- **Why stopped:** DSMB recommendation (futility)
- **Last updated:** 2020-05-06


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04341870

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04341870, "Study of Immune Modulatory Drugs and Other Treatments in COVID-19 Patients: Sarilumab, Azithromycin, Hydroxychloroquine Trial - CORIMUNO-19 - VIRO". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT04341870. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*